Moderna’s stock (MRNA) is trading 82% higher YTD into earnings, despite a 30% pullback in the past three weeks. Volatility is elevated, with the company scheduled to report second-quarter 2026 earnings before the US market opens Friday.
Analysts expect the biotechnology company to post a loss of US$2.06 per share, slightly narrower than the US$2.13 loss recorded in the same quarter last year. Revenue consensus sits at US$103.88 million, a 26.84% decline Y/Y. Current estimates for FY27 are far more bullish however, with the Street currently looking for $2.56billion in revenue, a 22.15% Y/Y growth rate.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Several factors could influence the stock after the print outside of the headline numbers. Any material shift in revenue guidance, particularly if management narrows the range, could prompt a re-rating. Commentary on partnership deals, regulatory progress for pipeline candidates, or updates on manufacturing efficiency will also be scrutinised.
Moderna’s share price action reflects a sharp contrast between strong year-to-date momentum and longer-term underperformance. Zooming out, the 82% gain this year pales in comparison to a five-year decline of 84.15%. Those who have been holding MRNA for numerous years will no doubt be well versed in the volatility, and tomorrow’s print is likely to deliver more of the same.
With volatility already high, an earnings event could see amplified trading, with options markets pricing a ~9.8% move in the stock following the print.
